Literature DB >> 26564206

Subantimicrobial-dose doxycycline monohydrate in dermatology.

Uwe Wollina1.   

Abstract

Subantimicrobial doxycycline is an anti-inflammatory drug that decreases cathelicidin, kallikrein 5, reactive oxygen species, nitric oxide, and matrix metalloproteinases. Clinical trials demonstrated a comparable efficacy to 100-mg doxycycline in papulopustular rosacea with improvement of inflammatory lesions, quality of life, and improved safety profile. Case series and case reports suggested efficacy in other inflammatory skin diseases. The response of papulopustular rash during targeted anticancer therapies is mixed. Further studies are needed.

Entities:  

Keywords:  Doxycycline; Inflammatory skin diseases; Subantimicrobial dosing

Mesh：

Substances：

Year:  2015        PMID： 26564206     DOI： 10.1007/s10354-015-0399-9

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN： 0043-5341


  35 in total

1.  Treatment of ocular rosacea with once-daily low-dose doxycycline.

Authors:  Bianka Sobolewska; Deshka Doycheva; Christoph Deuter; Ines Pfeffer; Martin Schaller; Manfred Zierhut
Journal:  Cornea       Date:  2014-03       Impact factor: 2.651

2.  An open-label, community-based, 12-week assessment of the effectiveness and safety of monotherapy with doxycycline 40 mg (30-mg immediate-release and 10-mg delayed-release beads).

Authors:  Guy F Webster
Journal:  Cutis       Date:  2010-11

3.  [Red scalp. A previously undescribed disease of the scalp?].

Authors:  K Thestrup-Pedersen; N Hjorth
Journal:  Ugeskr Laeger       Date:  1987-08-03

4.  Topical corticosteroid-induced rosacea-like dermatitis: a clinical study of 110 cases.

Authors:  Sanjay K Rathi; Leishiwon Kumrah
Journal:  Indian J Dermatol Venereol Leprol       Date:  2011 Jan-Feb       Impact factor: 2.545

Review 5.  Cutaneous adverse effects of targeted therapies: Part II: Inhibitors of intracellular molecular signaling pathways.

Authors:  James B Macdonald; Brooke Macdonald; Loren E Golitz; Patricia LoRusso; Aleksandar Sekulic
Journal:  J Am Acad Dermatol       Date:  2015-02       Impact factor: 11.527

Review 6.  Update on rosacea and anti-inflammatory-dose doxycycline.

Authors:  Brian Berman; Oliver A Perez; Deborah Zell
Journal:  Drugs Today (Barc)       Date:  2007-01       Impact factor: 2.245

7.  Retarded low-dose doxycycline for EGFR or MEK inhibitor-induced papulopustular rash.

Authors:  J Vaubel; E Livingstone; D Schadendorf; L Zimmer
Journal:  J Eur Acad Dermatol Venereol       Date:  2014-01-15       Impact factor: 6.166

8.  Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea.

Authors:  James Q Del Rosso; Guy F Webster; Mark Jackson; Marta Rendon; Phoebe Rich; Helen Torok; Mark Bradshaw
Journal:  J Am Acad Dermatol       Date:  2007-03-23       Impact factor: 11.527

9.  Late epidermal growth factor receptor inhibitor-related papulopustular rash: a distinct clinical entity.

Authors:  V Sibaud; E Tournier; H Roché; P Del Giudice; J P Delord; T Hubiche
Journal:  Clin Exp Dermatol       Date:  2015-05-11       Impact factor: 3.470

10.  Doxycycline indirectly inhibits proteolytic activation of tryptic kallikrein-related peptidases and activation of cathelicidin.

Authors:  Kimberly N Kanada; Teruaki Nakatsuji; Richard L Gallo
Journal:  J Invest Dermatol       Date:  2012-02-16       Impact factor: 8.551
View more
  3 in total

1.  Doxycycline attenuates breast cancer related inflammation by decreasing plasma lysophosphatidate concentrations and inhibiting NF-κB activation.

Authors:  Xiaoyun Tang; Xianyan Wang; Yuan Y Zhao; Jonathan M Curtis; David N Brindley
Journal:  Mol Cancer       Date:  2017-02-08       Impact factor: 27.401

2.  Otophyma, Rhinophyma and Telangiectatic Rosacea - A Rare Combination in a Female Patient.

Authors:  Uwe Wollina; Torello Lotti; Georgi Tchernev
Journal:  Open Access Maced J Med Sci       Date:  2017-07-19

3.  Rosacea Flare - Up after Photodynamic Therapy (PDT) for Field Cancerization and a Review on Adverse Events with PDT in General.

Authors:  Uwe Wollina; Alena Bitel; Aleksandra Vojvodic; Torello Lotti
Journal:  Open Access Maced J Med Sci       Date:  2019-08-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.